240 related articles for article (PubMed ID: 33101774)
21. Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab.
Ksienski D; Wai ES; Croteau NS; Freeman AT; Chan A; Fiorino L; Poonja Z; Fenton D; Patterson T; Irons S; Lesperance M
J Geriatr Oncol; 2020 Jun; 11(5):807-813. PubMed ID: 31937494
[TBL] [Abstract][Full Text] [Related]
22. Comparing survival in trial- versus routine-care advanced urothelial cancer patients on immune checkpoint blockade.
Wang LS; Hubbard RA; Mamtani R
Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5798. PubMed ID: 38680111
[TBL] [Abstract][Full Text] [Related]
23. The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
George S; Bell EJ; Zheng Y; Kim R; White J; Devgan G; Smith J; Lal LS; Engel-Nitz NM; Liu FX
Oncologist; 2021 Jul; 26(7):e1205-e1215. PubMed ID: 33955118
[TBL] [Abstract][Full Text] [Related]
24. Role of Checkpoint Inhibition in Localized Bladder Cancer.
Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
[TBL] [Abstract][Full Text] [Related]
25. Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer.
Graf RP; Fisher V; Creeden J; Schrock AB; Ross JS; Nimeiri H; Oxnard GR; Klempner SJ
Cancer Res Commun; 2022 Sep; 2(9):1037-1048. PubMed ID: 36922935
[TBL] [Abstract][Full Text] [Related]
26. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
Makrakis D; Talukder R; Diamantopoulos LN; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin VS; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Santos VS; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt ME; Grant M; Lythgoe MP; Pinato DJ; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Murgic J; Fröbe A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Di Lorenzo G; Joshi M; Isaacsson-Velho P; Buznego LA; Duran I; Moses M; Barata P; Sonpavde G; Yu EY; Wright JL; Grivas P; Khaki AR
BJU Int; 2022 Nov; 130(5):592-603. PubMed ID: 34597472
[TBL] [Abstract][Full Text] [Related]
27. Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review.
Graham J; Vogel A; Cheng AL; Bjarnason GA; Neal JW
Cancer Treat Rev; 2022 Nov; 110():102453. PubMed ID: 36037792
[TBL] [Abstract][Full Text] [Related]
28. Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types.
Torres AZ; Nussbaum NC; Parrinello CM; Bourla AB; Bowser BE; Wagner S; Tabano DC; George D; Miksad RA
Adv Ther; 2022 Jun; 39(6):2831-2849. PubMed ID: 35430670
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
Feld E; Harton J; Meropol NJ; Adamson BJS; Cohen A; Parikh RB; Galsky MD; Narayan V; Christodouleas J; Vaughn DJ; Hubbard RA; Mamtani R
Eur Urol; 2019 Oct; 76(4):524-532. PubMed ID: 31362898
[TBL] [Abstract][Full Text] [Related]
30. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
31. Real-World Clinical and Economic Outcomes and the Role of Bevacizumab in Patients With Non-Small-Cell Lung Cancer With Liver Metastases.
Wong WB; Wu N; Yang E; Davies J; Chae YK
J Oncol Pract; 2019 Oct; 15(10):e878-e887. PubMed ID: 31509482
[TBL] [Abstract][Full Text] [Related]
32. Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.
Griesinger F; Pérol M; Girard N; Durand-Zaleski I; Zacharias S; Bosquet L; Jänicke M; Quantin X; Groth A; Fleitz A; Calleja A; Patel S; Lacoin L; Daumont MJ; Penrod JR; Carroll R; Waldenberger D; Reynaud D; Thomas M; Chouaid C
Lung Cancer; 2022 Oct; 172():65-74. PubMed ID: 36007281
[TBL] [Abstract][Full Text] [Related]
33. Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.
Sheinson D; Wong WB; Wu N; Mansfield AS
Lung Cancer; 2020 May; 143():86-92. PubMed ID: 32276206
[TBL] [Abstract][Full Text] [Related]
34. Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice.
Nesline MK; Knight T; Colman S; Patel K
Clin Ther; 2020 Sep; 42(9):1682-1698.e7. PubMed ID: 32747004
[TBL] [Abstract][Full Text] [Related]
35. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
[TBL] [Abstract][Full Text] [Related]
36. Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.
Schwartzberg L; Korytowsky B; Penrod JR; Zhang Y; Le TK; Batenchuk C; Krug L
Clin Lung Cancer; 2019 Jul; 20(4):287-296.e4. PubMed ID: 31130450
[TBL] [Abstract][Full Text] [Related]
37. Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
Swami U; Haaland B; Kessel A; Nussenzveig R; Maughan BL; Esther J; Sirohi D; Pal SK; Grivas P; Agarwal N
J Urol; 2021 Mar; 205(3):709-717. PubMed ID: 33080152
[TBL] [Abstract][Full Text] [Related]
38. Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer.
Hosokawa S; Ichihara E; Bessho A; Harada D; Inoue K; Shibayama T; Kishino D; Harita S; Ochi N; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Jpn J Clin Oncol; 2021 Feb; 51(2):279-286. PubMed ID: 33049757
[TBL] [Abstract][Full Text] [Related]
39. The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy.
Tsai TH; Su PJ; Huang SY; Kuo MC; Lin CT; Wu CC; Luo HL; Chen CH; Chou CC; Liu TT; Huang CC; Tsai KL; Su YL
BMC Cancer; 2023 Sep; 23(1):871. PubMed ID: 37715113
[TBL] [Abstract][Full Text] [Related]
40. Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
La-Beck NM; Nguyen DT; Le AD; Alzghari SK; Trinh ST
Pharmacotherapy; 2020 Mar; 40(3):239-255. PubMed ID: 31930528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
